Bluebird Bio, a biotech company with three approved gene therapies but no way of commercialising them, will be sold to private equity firms Carlyle and SK Capital Partners in a $29 million deal. Bluebird’s therapies offered rare disease treatments, including beta thalassemia and cerebral adrenoleukodystrophy; a third did not include the necessary financial cover of a PRV required to finance its intense manufacturing processes and was rejected three times by the FDA, leading to debt and restructuring. The sale could bring Bluebird up to $67 million more if the therapies reach a sales target.
New Guidelines: Cybersecurity Resilience in the Healthcare Industry
In response to growing cyber threats, healthcare cybersecurity requirements are set to tighten, shifting towards resilience rather than prevention. The proposed changes include an emphasis
